Showing results (931-940 of 3,591) with videos related to
Sort By:
Pageof 360
Journal of Viral Hepatitis|November 18, 2018
Applying core theory and spatial analysis to identify hepatitis C virus infection "core areas" in British Columbia, CanadaZahid A Butt, Sunny Mak, Dionne Gesink, et al.Journal of Viral Hepatitis|November 13, 2018
Efficacy and safety of antiviral treatment on blocking the mother-to-child transmission of hepatitis B virus: A meta-analysisJiahui Song, Fan Yang, Shuo Wang, et al.Journal of Viral Hepatitis|November 14, 2018
High response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programmeJasmine Schulkind, Brian Stephens, Farsana Ahmad, et al.Journal of Viral Hepatitis|March 29, 2019
Electronic health record year and country of birth testing and patient navigation to increase diagnosis of chronic viral hepatitisAndrew de la Torre, Maliha Ahmad, Farhan Ayoub, et al.Journal of Viral Hepatitis|August 27, 2019
Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: A cohort studyBeth Catlett, Francois M J Lamoury, Sahar Bajis, et al.Journal of Viral Hepatitis|September 15, 2019
p38 mitogen-activated protein kinase impairment of innate immune cells is a characteristic feature of HBeAg-negative chronic hepatitis BMarianna Bakarozi, Athanasios Mavropoulos, Dimitrios P Bogdanos, et al.Journal of Viral Hepatitis|August 17, 2019
Hepatitis B core-related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinomaWai-Pan To, Lung-Yi Mak, Danny Ka-Ho Wong, et al.Journal of Viral Hepatitis|January 22, 2021
Entecavir-induced interferon-λ1 suppresses type 2 innate lymphoid cells in patients with hepatitis B virus-related liver cirrhosisSi-Qi Wang, Yue Shen, Jing Li, et al.Journal of Viral Hepatitis|January 23, 2021
Dynamic evaluation of hepatocellular carcinoma prediction models in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatmentSakura Kirino, Nobuharu Tamaki, Masayuki Kurosaki, et al.Journal of Viral Hepatitis|January 16, 2021
Antiviral treatment for hepatitis C is associated with a reduced risk of atherosclerotic cardiovascular outcomes: A systematic review and meta-analysisXin Su, Xin Zhao, Jia-Long Deng, et al.Pageof 360